GHK-CU

GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine (GHK) bound to a copper ion. It occurs naturally in human plasma, saliva, and urine, and circulating levels decline with age — from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60 (Pickart et al., BioMed Research International, 2015). That age-related decline, plus decades of laboratory work on wound repair, is why it became one of the most-used peptides in cosmetic skincare.

The single most important thing to understand about GHK-Cu is that it is really two different products wearing one name:

• Topical GHK-Cu — a legal cosmetic ingredient with small controlled human studies behind skin-appearance claims. The evidence is real but modest, and much of it was produced or reviewed by researchers with commercial ties to copper-peptide products.

• Injectable GHK-Cu — a gray-market research chemical with essentially no published human safety or efficacy trials. Every systemic claim made for it is extrapolated from cell-culture and animal data.

Evidence tier: small controlled human studies for topical cosmetic endpoints; preclinical only for systemic or injectable use. GHK-Cu is not an approved drug anywhere for any indication.

GHK has an unusually high affinity for copper(II) and shuttles it into cells, where copper is a required cofactor for enzymes such as lysyl oxidase (which cross-links collagen and elastin) and superoxide dismutase (an antioxidant enzyme). Beyond copper delivery, the peptide itself acts as a signaling molecule. In cell-culture and animal models, GHK-Cu has been shown to:

• stimulate fibroblast production of collagen, elastin, and glycosaminoglycans;
• modulate matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), the enzymes that balance tissue breakdown against rebuilding;
• promote angiogenesis and attract immune and repair cells to wound sites;
• dampen inflammatory signaling, including TNF-alpha-driven responses in wounded tissue (Canapp et al., Veterinary Surgery, 2003).

Gene-profiling work has produced the most striking — and most oversold — numbers in this literature. The Broad Institute's Connectivity Map data suggest GHK alters expression of a large fraction of tested human genes, a finding summarized in a 2018 review claiming effects on roughly a third of profiled genes (Pickart & Margolina, Int. J. Mol. Sci., 2018). Both major GHK reviews were written by researchers at Skin Biology, a company that sells copper-peptide products, so their framing should be read as an informed but interested party's synthesis, not an independent audit.

GHK-Cu has no approved medical indication. In practice it appears in three contexts:

• Cosmetic skincare — serums and creams marketed for fine lines, skin density, and elasticity in photoaged skin; also common in post-procedure products after microneedling or laser resurfacing.

• Hair products — copper-peptide shampoos and topicals aimed at hair thinning, building on older animal data and on work with the related peptide AHK-Cu.

• Gray-market injectables — lyophilized vials sold "for research use," reconstituted and self-injected subcutaneously for claimed systemic anti-aging or recovery effects that no human trial has tested.

A copper-peptide wound gel (Iamin, developed by ProCyte) reached human trials for diabetic foot ulcers in the 1990s but was never approved as a drug; that program's history is recounted in the Pickart reviews cited above. The compound's only regulatory identity today is as a cosmetic ingredient.

Topical and injectable GHK-Cu have very different risk profiles, and only the first has meaningful human data.

Topical use. In the published cosmetic studies — several hundred participant-exposures across 12-week facial trials — GHK-Cu creams were reported as well tolerated (Pickart & Margolina, 2018). Practical considerations that do come up:

• Local irritation — redness, stinging, or itching, more likely on compromised skin barriers or at higher concentrations; standard patch-testing logic applies.
• Blue staining — the copper complex is intensely blue and can temporarily tint skin, fabric, or light hair at high concentrations.
• Post-procedure timing — in the one independent randomized trial of GHK-Cu products after CO2 laser resurfacing (n=13), patients using them reported higher satisfaction, but objective measures of redness and wrinkles showed no difference from control skincare (Miller et al., Arch. Facial Plast. Surg., 2006).

Copper exposure. Copper is an essential mineral with a narrow comfort zone: the adult RDA is 900 mcg/day and the tolerable upper intake level is 10 mg/day, with excess intake linked to gastrointestinal symptoms and liver injury (NIH Office of Dietary Supplements). Topical absorption through intact skin is low, and the copper dose in a cosmetic serum is small. Injection changes the equation: it bypasses the intestinal regulation that normally limits copper uptake, and no one has published data on what repeated parenteral GHK-Cu does to copper balance in humans. People with copper-handling disorders such as Wilson disease have a specific, obvious reason to avoid any copper-delivering product.

Injectable use. Commonly reported issues in community logs are injection-site pain (a characteristic "sting"), redness, and welts. The deeper problem is what is not known: there are no human safety trials of injectable GHK-Cu at any dose, no pharmacokinetic studies, and no quality oversight of the unregulated vials being sold.

GHK-Cu is a small (~403 Da) hydrophilic peptide-copper complex. In topical products it acts primarily at the skin; how much reaches deeper tissue is formulation-dependent and poorly quantified. No human pharmacokinetic data exist for injected GHK-Cu.

One number worth doing the arithmetic on: copper is about 16% of GHK-Cu by weight, so a 2 mg injection delivers roughly 0.3 mg of elemental copper. That is well under the 10 mg/day oral upper limit — but the oral limit assumes intestinal absorption acting as a gatekeeper, which injection bypasses entirely. Nobody has measured what that means over months of use.

GHK-Cu appears in serums, creams, foams, hair topicals, microneedling cocktails, and lyophilized injectable vials. In cosmetic formulas it is often stacked with other signal peptides such as Matrixyl (palmitoyl pentapeptides) and SNAP-8, or with the copper peptide AHK-Cu in hair products.

A persistent formulation question is whether GHK-Cu can be layered with vitamin C or retinoids. There are no published clinical studies of these combinations; the concern is chemistry-level — ascorbic acid is a reducing agent that can interact with copper ions in solution — which is why many formulators separate them into different products or application times rather than co-formulating. Treat brand claims in either direction as unverified.

The literature splits cleanly into three tiers:

• Human cosmetic trials (topical). The most-cited facial studies — including a 12-week trial in 71 women reporting improved skin density, elasticity, and wrinkle depth, and a 20-woman study reporting increased collagen versus vitamin C and tretinoin creams — were industry-run and mostly presented at conferences rather than published as standalone peer-reviewed papers; they are known today mainly through the Skin Biology reviews (Pickart & Margolina, 2018). The one fully independent randomized trial (post-laser skincare, n=13) found higher patient satisfaction but no objective advantage (Miller et al., 2006).

• Animal wound and hair models. In 24 rats with ischemic open wounds, topical GHK-Cu roughly doubled the rate of wound closure (64.5% vs 28.2% area reduction by day 13) and lowered TNF-alpha and MMP levels (Canapp et al., 2003). A copper-binding peptide enlarged hair follicles in fuzzy rats with an effect compared to topical minoxidil (Uno & Kurata, J. Invest. Dermatol., 1993).

• Exploratory systemic biology. A genomics study of emphysema-damaged lung tissue identified GHK as a compound that could reverse the disease-associated gene-expression signature in COPD patient fibroblasts (Campbell et al., Genome Medicine, 2012) — intriguing computational-plus-cell-culture work, not a treatment trial.

What is missing is exactly what injectable sellers imply exists: randomized human trials of systemic GHK-Cu for anything. See the full evidence review for study-by-study detail.

For deeper dives on this peptide, see:

• GHK-CU benefits and areas of interest
• GHK-CU side effects and safety context
• GHK-CU dosing concepts (educational)
• GHK-CU research and evidence overview

What does GHK-Cu actually do for skin? In small 12-week facial studies, GHK-Cu creams improved measured skin density, elasticity, and fine-line depth in photoaged skin (reviewed here). The plausible mechanism — stimulating collagen and elastin production while moderating the enzymes that break them down — is well documented in cells and animals. Expect the magnitude of a good cosmetic ingredient, not a procedure.

Is GHK-Cu safe to inject? Unknown — and that is the honest answer. There are no published human trials of injectable GHK-Cu, so there is no safety dataset, no established dose, and no long-term data on parenteral copper delivery. Reported short-term effects in community logs are mostly injection-site pain and irritation, but absence of trial data is not evidence of safety.

Does GHK-Cu regrow hair? Not proven in humans. The supporting evidence is animal and ex vivo: follicle enlargement in fuzzy rats (Uno & Kurata, 1993) and elongation of cultured human follicles by the related peptide AHK-Cu (Pyo et al., 2007). No controlled trial has shown copper peptides regrow hair on human scalps the way minoxidil or finasteride have.

What concentration should a topical product have? Commercial serums generally label 1–2% GHK-Cu; a deep-blue color is a rough visual sign of meaningful copper-peptide content. The clinical studies used proprietary creams without standardized concentrations, so there is no evidence-backed "correct" percentage — 1% is the de facto market norm.

Can I use GHK-Cu with vitamin C or retinol? No published study has tested these combinations. The commonly cited conflict with vitamin C is a theoretical chemistry concern (ascorbic acid can reduce copper ions in solution), which is why many routines apply them at different times of day. Claims that the combination "deactivates" or is "fine" are both unverified.

Is GHK-Cu FDA approved? No. It is legal in cosmetics as an ingredient, but it is not an approved drug for any indication, and injectable GHK-Cu is sold outside any regulatory framework.